Russia creates additional obstacles for more active supplies of original drugs
The Russian Ministry of Health has expanded the list of domestic vital drugs by inclusion of two new drugs which is contrary to initial calls of the local patient community to include at least eight original drugs, reports The Pharma Letter’s local correspondent.
According to representatives of patients, that was supposed to improve the level of provision of Russian patients with some important and original drugs.
One of the approved drugs is Lorviqua (lorlatinib) from US pharma giant Pfizer (NYSE: PFE), which is used to treat ALK+ non-small cell lung cancer. According to representatives of the Russian Blokhin National Medical Research Center of Oncology, the drug shows the "best results" for this type of cancer and should be included in the list.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze